Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
20091.4k citationsMarc A. Pfeffer, Emmanuel A. Burdmann et al.New England Journal of Medicineprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Peter Ivanovich
Since
Specialization
Citations
This map shows the geographic impact of Peter Ivanovich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Ivanovich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Ivanovich more than expected).
This network shows the impact of papers produced by Peter Ivanovich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Ivanovich. The network helps show where Peter Ivanovich may publish in the future.
Co-authorship network of co-authors of Peter Ivanovich
This figure shows the co-authorship network connecting the top 25 collaborators of Peter Ivanovich.
A scholar is included among the top collaborators of Peter Ivanovich based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Peter Ivanovich. Peter Ivanovich is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Polenaković, Momir, Alı Başçı, Ljubica Djukanović, et al.. (2013). 20 years since the establishment of the BANTAO association (Balkan Cities Association of Nephrology, Dialysis, Transplantation and Artificial Organs).. PubMed. 34(2). 181–213.3 indexed citations
3.
Pfeffer, Marc A., Emmanuel A. Burdmann, Mark E. Cooper, et al.. (2009). A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. New England Journal of Medicine. 361(21). 2019–2032.1429 indexed citations breakdown →
4.
Pfeffer, Marc A., Scott D. Solomon, Ajay Singh, Peter Ivanovich, & John J.V. McMurray. (2005). Uncertainty in the treatment of anemia in chronic kidney disease.. PubMed. 6 Suppl 3. S35–41.6 indexed citations
5.
Stegmayr, Bernd, Peter Ivanovich, J.M. Korach, et al.. (2004). World Apheresis Registry (abstract P165). The International Journal of Artificial Organs. 27(7). 638.
Colì, L., Mario Bonomini, Gaetano La Manna, et al.. (1998). Clinical Use of Profiled Hemodialysis. Artificial Organs. 22(9). 724–730.15 indexed citations
Shah, Gaurang, Howard A. Nelson, Arthur J. Atkinson, et al.. (1979). Effect of hemoperfusion on the pharmacokinetics of digitoxin in dogs.. PubMed. 93(3). 370–80.5 indexed citations
Ivanovich, Peter, et al.. (1969). Acute hemolysis following hemodialysis.. PubMed. 15. 316–20.20 indexed citations
20.
Ivanovich, Peter, et al.. (1966). A compact hydraulic proportioning system for hemodialysis.. PubMed. 12. 357–62.10 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.